Journal
MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 9, Issue -, Pages 47-49Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2016.06.007
Keywords
Multiple sclerosis; Fingolimod; Cryptococcus; Lymphopenia
Categories
Funding
- National Multiple Sclerosis Society
Ask authors/readers for more resources
Fingolimod (Gilenya, Novartis) is an oral sphingosine-1-phosphate analogue used in the treatment of relapsing multiple sclerosis (MS). Fingolimod treatment is associated with relative lymphopenia and was associated with an increased risk of herpes infection in clinical trials. In the post-marketing setting, fingolimod has been associated with several cases of cryptococcal meningitis, recently prompting an update to its prescribing information. To date, all cases have been associated with active treatment with fingolimod. In this report, we describe the first case of cryptococcal meningitis diagnosed after fingolimod discontinuation. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available